Novo Nordisk's Wegovy Under Review in EU for Cardiovascular Risk Reduction Indication

Intelligent Finance APP learned that this week, the European Medicines Agency (EMA), the EU's drug regulatory body,EMA) An expert panel will consider expanding the use of Novo Nordisk's (NVO.US) weight-loss therapy Wegovy to reduce the risk of stroke and heart attack.

The agenda for the monthly meeting of the EMA's Committee for Medicinal Products for Human Use (CHMP) on Monday showed that the group will review data supporting broader use of the drug, known generically as semaglutide.

GLP-1 receptor agonists are currently approved in the EU for weight loss in adults as an adjunct to diet and physical activity.

Positive opinions at the meeting will lead to the region's approval for its use in adults to reduce the risk associated with adverse cardiovascular events such as stroke and myocardial infarction.

The basis of this review isNovo NordiskSELECT Phase 3 Trial for Wegovy Shows Semaglutide Reduces Adverse Cardiovascular Events by 20% in Obese or Overweight Adults